



PRESS RELEASE

18 September 2019, 8.00 CET

Biovica invites to telephone conference/audiocast

Uppsala, Sweden, September 18, 2019. Biovica invites investors, analysts and the media to a presentation where Anders Rylander, CEO, and Mattias Bergqvist, Clinical Development Director, comments on today's announcement. The presentation will be held on 19 September 2019 at 10:00 CET and can be followed via telephone conference or audiocast.

The presentation will be held in English and will be followed by a questions and answers session. Questions can be asked via the telephone conference or in written form via the audiocast. No pre-registration is needed.

Participant dial in number

DK: +4578150109

SE: +46856642703

UK: +443333009030

US: +18338230589

The presentation can also be viewed live at:

<https://tv.streamfabriken.com/2019-09-19-biovica-international-press-conference>

Afterwards, a recording of the presentation will be available at the same page.

Contact

Anders Rylander, CEO Biovica.

Phone: +46 (0)18 444 48 35,

E-mail: anders.rylander@biovica.com

Biovica – Best Possible Treatment from Day One.

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE labelled and MPA registered. Appointed Certified Adviser is FNCA Sweden AB, info@fnca.se, +46 8 528 00 399.

Webb www.biovica.com

Contact info@biovica.com